• 1
    Thieblemont C,Berger F,Dumontet C, et al. Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. Blood 2000; 95: 802806.
  • 2
    Zinzani PL,Magagnoli M,Galieni P, et al. Nongastrointestinal low-grade mucosa-associated lymphoid tissue lymphoma: Analysis of 75 patients. J Clin Oncol 1999; 17: 1254.
  • 3
    Zucca E,Conconi A,Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood 2003; 101: 24892495.
  • 4
    Isaacson PG. Update on MALT lymphomas. Best Pract Res Clin Haematol 2005; 18: 5768.
  • 5
    Ko YH,Kim CW,Park CS, et al. REAL classification of malignant lymphomas in the Republic of Korea: Incidence of recently recognized entities and changes in clinicopathologic features. Hematolymphoreticular Study Group of the Korean Society of Pathologists. Revised European-American lymphoma. Cancer 1998; 83: 806812.
  • 6
    Oh SY,Ryoo BY,Kim WS, et al. Nongastric marginal zone B-cell lymphoma: Analysis of 247 cases. Am J Hematol 2007; 82: 446452.
  • 7
    Sretenovic M,Colovic M,Jankovic G, et al. More than a third of non-gastric malt lymphomas are disseminated at diagnosis: A single center survey. Eur J Haematol 2009; 82: 373380.
  • 8
    Zucca E,Bertoni F,Stathis A,Cavalli F. Marginal zone lymphomas. Hematol Oncol Clin North Am 2008; 22: 883901.
  • 9
    Ferreri AJ,Zucca E. Marginal-zone lymphoma. Crit Rev Oncol Hematol 2007; 63: 245256.
  • 10
    Oh SY,Kwon HC,Kim WS, et al. Nongastric marginal zone B-cell lymphoma: A prognostic model from a retrospective multicenter study. Cancer Lett 2007; 258: 9097.
  • 11
    Zinzani PL,Stefoni V,Musuraca G, et al. Fludarabine-containing chemotherapy as frontline treatment of nongastrointestinal mucosa-associated lymphoid tissue lymphoma. Cancer 2004; 100: 21902194.
  • 12
    Nuckel H,Meller D,Steuhl KP,Duhrsen U. Anti-CD20 monoclonal antibody therapy in relapsed MALT lymphoma of the conjunctiva. Eur J Haematol 2004; 73: 258262.
  • 13
    Tobinai K,Ishizawa KI,Ogura M, et al. Phase II study of oral fludarabine in combination with rituximab for relapsed indolent B-cell non-Hodgkin lymphoma. Cancer Sci 2009; 100: 19511956.
  • 14
    Raderer M,Wohrer S,Streubel B, et al. Activity of rituximab plus cyclophosphamide, doxorubicin/mitoxantrone, vincristine and prednisone in patients with relapsed MALT lymphoma. Oncology 2006; 70: 411417.
  • 15
    Oh SY,Kim WS,Lee DH, et al. Phase II study of Gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trial. Invest New Drugs, in press.